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Supporting Formulary Decisions: The Discovery of New Facts or Constructed Evidence? 
Paul C Langley, PhD 
College of Pharmacy University of Minnesota, Minneapolis MN 
 
Abstract 
A critical question, given the growing importance of more targeted therapies to support personalized and precision medicine, is the 
credibility of the evidence base to support formulary decisions and pricing. On the one hand, for those who subscribe to the reference 
case model of the National Institute of Health and Care Excellence (NICE) in the UK, the decision rests upon the creation of modeled 
or simulated imaginary worlds and the application of threshold willingness-to-pay cost-per-QALY thresholds. On the other hand, for 
those who subscribe to the standards of normal science, the decision rests upon the ability to evaluate competing claims, both clinical 
and cost-effective, in a timeframe that is meaningful to a formulary committee. If we subscribe to the scientific method where the 
focus is on the discovery of new facts, untestable claims for clinical benefit and cost-effectiveness, such as created claims for lifetime 
cost per-quality-adjusted discounted  life years (QALYs), are properly relegated to the category of pseudoscience. We have no idea, 
and will never know, whether the claims are right or even if they are wrong. If formulary decisions are to respect the standards of 
normal science then there has to be a commitment to claims evaluation. A willingness to accept new products provisionally, subject 
to an agreed protocol to support the evaluation of clinical and cost-effectiveness claims.  This dichotomy between the standards of 
normal science and pseudoscience is explored in the context of published claims for cost-effectiveness and recommendations for 
product pricing in the US. 
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Introduction: Demarcation 
If we are to distinguish credible from non-credible claims 
made for pharmaceutical products and devices, we need to 
address what Karl Popper has called the ‘demarcation 
problem’ 1 2. What distinguishes  those claims that meet the 
standards of normal science from those that might be 
described as pseudoscientific? Although science is not a 
monolithic activity, spanning the spectrum from hard science 
to soft science, the common element is the construction of 
empirically evaluable theories and hypotheses. From this 
perspective, unless we want to reject the standards of normal 
science, many pharmacoeconomic studies cross the line 
between science and pseudoscience. We have studies, on the 
one hand, that meet the required standards with hypotheses 
being evaluated through experimentation and systematic 
observation, while on the other hand we have modeled or 
simulated claims that clearly fail the criteria of normal science 
and are best seen as pseudoscience in their construction of 
imaginary worlds 3. 
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Probably the best example of an imaginary world is the 
National Institute for Health and Care Excellence (NICE) 
reference case 4.  The limitations of the constructed 
reference case approach to supporting clinical acceptance of 
pharmaceutical products and devices is well established 5 6. 
Although there is the appearance of modeled or simulated 
claims embracing scientific standards in input assumptions 
and the construction of the core mechanism corresponding to 
the natural course of a chronic disease, the fact is that the 
modeled or simulated claims are entirely synthetic. The 
degree of belief in the models rests upon an acceptance of its 
correspondence to reality, a correspondence that necessarily 
entails its claims for product performance 7. The Achilles heel 
is that simulations can be challenged and competing 
simulation constructed. Even in the context of the NICE single 
technology assessment process, contracted Evidence Review 
Groups (ERGs) can dispute the imaginary world’s model or 
simulation presented by a manufacturer, and in turn have 
their ‘new world’ challenged by the NICE Advisory Group. 
 
In the US, the equivalent construct is found in the standards 
recommended by the Academy of Managed Care Pharmacy 
(AMCP) Format for Formulary Submissions 8. A recent 
commentary on the latest Version 4 of the AMCP Format 
details the apparent lack of concern with establishing the 
value case for pharmaceutical products and devices on a 
robust evidence-based platform, instead relying upon 
modeled or simulated worlds that track the natural course of 
a disease 9. These imaginary constructs generate long-term or 
lifetime claims for clinical endpoints and incremental cost-
per-quality adjusted life year (QALY) claims that are clearly 
impossible to evaluate. Indeed, one interpretation is that 
there was no intention of ever generating testable claims. 
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Formulary committees in receipt of an AMCP Format driven 
submission, with competing product claims expressed in 
lifetime cost-per-QALY terms, suitably discounted over 10, 20 
or more years, are expected to take the claim at face value as 
an input to determine the appropriate formulary tier position 
and price.  
 
If we cast our net a little wider, recent reviews of cost-
effectiveness studies published in two journals, 
PharmacoEconomics and the Journal of Medical Economics, 
concluded that none of the published papers met the 
standards of normal science in generating claims for 
competing products that could be evaluated experimentally 
or through systematic observation 10 11. Both reviews pointed 
to the acceptance of QALYs as the preferred endpoint with 
claims expressed in incremental cost per QALY terms. The 
fact that lifetime cost-per-QALY claims were impossible to 
evaluate and were never intended to be evaluated was not 
explored. The further point that no health care system 
collects QALYs on a regular basis was not raised.  
 
The purpose of this review is to explore the extent to which 
the reference case approach to establishing value for 
competing pharmaceutical products, devices and 
interventions is still pursued in the US. The particular focus 
will be on modeled claims for cost-effectiveness and 
consequent threshold driven recommendations for product 
pricing undertaken by the Institute for Clinical and Economic 
Review (ICER). The ICER has been chosen, not only because of 
its high profile, but also because the value and claims 
methodology closely follows the NICE scoping and product 
submission process, to include a reliance upon a reference 
case standard.   
 
Imaginary Worlds in Cost Effectiveness Analysis 
Imaginary modeled worlds are extremely popular in cost-
effectiveness analysis. Whether the popularity is a reflection 
of a lack of interest in developing evaluable claims for 
pharmaceutical products and devices that can be traced back 
to the release of the draft Australian guidelines in 1990, the 
acceptance of the reference case cost per QALY models 
mandated by NICE and a number of other health care 
systems or merely the continuation of a trend that can be 
traced back to the 1980s is an open question 12. In any event, 
there is widespread acceptance of the imaginary world 
approach to establishing the value of competing 
pharmaceutical products and devices. This acceptance 
embraces assessment agencies in New Zealand and Ireland as 
well as acceptance by professional groups, specifically the 
International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) 13 14 15 16 17. This willingness to embrace the 
construction of imaginary worlds may simply reflect belief in 
equivalence, where, with sufficient correspondence between 
the imaginary world and some perception of reality, the 
untestable conclusions for comparative product value are 
necessarily entailed 18. Truth, in this belief system, is by 
consensus.  
 
If we accept that those advocating reference case modeling 
are not interested in developing model frameworks that have 
the potential to generate testable hypotheses, then this puts 
those models in the pseudoscience category. The predictions 
of the imaginary world, expressed all too often in lifetime 
cost per QALY terms are clearly never intended to be open to 
empirical evaluation. Claims from the model are immune to 
falsification.  
 
A curious feature of the imaginary world modeling standard is 
that while, on the one hand, it attempts to correspond to 
reality in the representation of the course of a chronic 
disease through the application of, for example, Markov 
processes, on the other hand the methodology typically 
rejects any attempt, for example, to introduce adherence and 
persistence behavior and the impact of discontinuation, other 
than that reported in randomized clinical trials (RCTs) on the 
relative clinical benefits of competing products. The modeling 
is ‘of this world’ yet ‘not of this world’ (or a future world). The 
assumptions build into this imaginary world methodology 
clearly preclude testable claims. The models are simply 
commercial products.  
 
ICER Case Studies 
Three ICER reports have been selected for review. These are: 
(i) Mepolizumab in Severe Asthma; (ii) Insulin Degludec in 
Diabetes; and (iii) Novel Combination Therapies in Genotype 
1 Chronic Hepatitis C Infection 19 20 21. While this is not a 
systematic review and selection, the reports chosen are 
stated by their authors as following the ICER value 
methodology. The focus here is on the cost-outcomes 
modeling and the application of willingness to pay thresholds 
to constructed cost-per-QALY lifetime outcome claims. 
 
 I: Mepolizumab in Severe Asthma  
In March 2016, ICER through the California Technology 
Assessment Forum, released the final report for mepolizumab 
(Nucala®; GlaxoSmithKline) for the treatment of severe 
asthma with eosinophilia. The proposed model generated 
estimates of cost-effectiveness for the product utilized a 
Markov cohort framework, cycle length of 2-weeks, with 
three primary health states: asthma non-exacerbation state, 
an asthma exacerbation state and death. The asthma 
exacerbation state included three mutually exclusive sub-
categories: an asthma related event that required an oral 
corticosteroid burst, asthma related-ED visit or asthma 
related hospitalization. The model structure was similar to 
other published asthma cost-effectiveness models where the 
intervention was modeled against the standard of care. 
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The base case for the mepolizumab  model was a lifetime 
horizon; again, apparently consistent with other models. 
Given the uncertainty around duration of treatment, the 
impact of multiple treatment time horizons was captured 
through a sensitivity analysis. The treatment effect observed 
during the product randomized controlled trials (RCTs) trials 
was assumed to be consistent throughout the duration of the 
model time horizon. All costs and outcomes were discounted 
at 3% with direct healthcare costs only considered. 
 
The hypothetical population characteristics for the model 
mirrored the mepolizumab exacerbation RCT population. 
There was an assumed allowance for inappropriate dosing 
linked to adverse event costs and disutility. Utilities were 
assigned to all health states in the model. For the non-
exacerbation health states these were mapped by algorithm 
from the St George’s Respiratory Questionnaire to the EQ-5D. 
For the exacerbation, health states utilities were assumed to 
be the same across treatment strategies. Given a dearth of 
utility data for these health states, the actual scores were 
taken as averages from the exacerbation health states.  
Over a lifetime treatment horizon the model yielded an 
estimated 23.96 avoided exacerbations (non-discounted) per 
patient receiving mepolizumab with the standard of care 
versus standard of care alone. The incremental cost per 
exacerbation averted was $24,626. There was an estimated 
gain of 1.53 QALYs relative to standard of care. This resulted 
in a cost-effectiveness estimate of $385,546 per QALY gained.   
 
Clearly, these modeled claims are not intended to be 
evaluated. Apart from modifying parameters within the 
model and producing other estimates for lifetime 
exacerbations avoided, lifetime direct costs and lifetime cost-
per-QALY, the outcomes with their high level of precision, are 
immune to failure. Applying cost-effectiveness thresholds of 
$50,000, $100,000 and $150,000, ICER concluded from their 
model that to achieve a cost effectiveness threshold of 
$150,000 the price per mepolizumab vial  would need to be 
$8932 ($12,116) annually, a 63% discount from the $2,500 
WAC ($32,500 per annum). Higher discounts would have to 
apply for lower cost-effectiveness thresholds. 
 
II: Insulin Degludec in Diabetes 
In March 2016, ICER again through the California Technology 
Assessment Forum, released the final report for insulin 
degludec (Tresiba®, Novo Nordisk A/S) for the treatment of 
diabetes  . To generate hypothetical predictions for the cost-
effectiveness of insulin degludec compared to insulin glargine 
U100, ICER utilized the UKPDS OM2 model to evaluate the 
differential treatment effects for those 30 years and over 
with any duration of diabetes and on a platform which is 
claimed to represent the typical trajectory for diabetes 
patients. The hypothetical target populations for the analysis 
were persons aged 18 years and over with either type 1 or 
type 2 diabetes mellitus (DM). In the latter group 
hypothetical patients taking basal only insulin were 
considered separate from those taking basal-bolus insulin. 
The demographic and clinical characteristics of the 
hypothetical patient cohorts were from the respective insulin 
degludec RCTs. 
 
The time horizon for the cost-effectiveness analysis was the 
hypothetical cohort lifetime extrapolated up to 70 years from 
the short term trial results of 6 to 12 months. The primary 
comparator for insulin degludec was insulin glargine U100. 
The model excluded insulin switching or other changes in 
therapy. The analysis focused on the hypothetical avoidance 
of hypoglycemic events, other adverse events, direct medical 
costs and reductions in health related quality of life. As the 
UKPDS OM2 does not include hypoglycemia as an outcome, 
the ICER modeling included hypoglycemia together with costs 
and disutilities for each event in a hypothetical sub-model. 
Each hypoglycemic event differentiated as mild/moderate 
daytime, mild/moderate nocturnal and severe was modeled 
from a patient level meta-analysis of insulin degludec clinical 
trials. Each event was assigned an associated cost and 
disutility. Disutilities were literature based. QALYs and costs 
were discounted at 3% per year.  
 
The lifetime hypothetical base case analysis yielded similar 
rates of hypoglycemic events in the type 1 DM population for 
the two therapies. In the type 2 DM hypothetical population 
there were QALY differences but not differences in costs, as 
these were assumed to apply only to severe hypoglycemic 
events. For type 2 DM patients on basal only therapy, the 
base case assumptions resulted in a cost/QALY ratio of 
$353,020 for insulin degludec compared to insulin glargine. 
For those on basal-bolus therapy the ratio was 
$166,644/QALY. The report concluded that to achieve a cost-
effectiveness ratio of $150,000 per QALY gained there would 
need to be a cost reduction of 8% and 2% respectively in the 
basal only and basal-bolus populations. 
 
III: Novel Combination Therapies in Chronic Hepatitis C 
A multistate Markov model was constructed to determine the 
hypothetical cost-effectiveness of six treatment regimens for 
HCV genotype 1. Two of therapies were interferon based 
(peg-interferon + ribavirin [PR] and sofosbuvir + PR) and the 
remaining four interferon free therapies (sofosbuvir + 
ribavirin; simeprevir + sofosbuvir; ledipasvir/sofosbuvir 8/12; 
ledipasvir/sofosbuvir 12). The model was designed to capture 
the net costs, health benefits and ICERs of these therapies, to 
include how these might hypothetically vary if treatments 
were delayed to a later stage in disease progression. The 
model was intended to portray the lifetime progression of 
HCV based on the fibrosis stage of the disease, together with 
the impact of regression of liver damage after successful 
treatment. The comparative effectiveness of treatments was 
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measured primarily in terms of QALYs together with the 
incidence of serious HCV-related complications.  
 
All results were presented for the patients’ lifetime and 
discounted at 3%. Separate analyses were conducted for 
treatment-naïve and experienced patients, and whether 
patients have cirrhosis. Results were also presented for the 
treatment strategies of ‘treat all’ or ‘wait until more 
advanced disease. Results were also presented for a mixed 
cohort of treatment naïve and experienced patients. Health 
benefits were adjusted for the discontinuation rates reported 
in the various clinical trials. 
 
The hypothetical patient population was assumed to weigh 
75kg and be 60 years of age. These criteria were based on 
adjusted data from the 2010 National Health and Nutrition 
Examination Survey (NHANES). The distribution of patients 
across fibrosis stages was based on empirical assessments of 
individuals with known HCV infection. The model did not 
distinguish patients by viral concentrations, sex or rates, 
although the study report admitted that these might affect 
treatment outcomes and disease progression. 
 
Lifetime costs were focused on the direct medical costs and 
covered drug costs, treatment related costs, other health 
care costs and adverse event costs. The unit costs (with a 
sensitivity band) were not expected to change over the 
patients’ lifetime, although they were discounted. Utility 
values were estimated from the HCV literature, 
encompassing 10 HCV states (including death) and 5 utilities 
for states after sustained virologic response per Markov cycle. 
 
Lifetime discounted QALYs, costs and ICERs were calculated 
for each regimen in comparison with the next least costly 
regimen. For completeness, each treatment option was also 
compared alternatively with no treatment as well as peg-
interferon as a universal historical control. A range of 
scenarios in which alternative discontinuation rates, the 
distribution of the patient cohort by fibrosis stage, different 
cost of care gradients and the cohort’s age were altered were 
also presented. 
 
The base-case result, which reflects the values of inputs that 
were believed to be most accurate and relevant, for 
treatment naïve and a treat all strategy with peg-interferon 
yielded an ICER for peginterferon of $11,385 compared to no 
treatment (a QALY gain of 1.51 years). The next lifetime 
lowest cost strategy of ledipasvir/sofosbuvir 8/12 generated 
an ICER of $20,132 and a QALY gain of a further 1.41 years. All 
other sofosbuvir-based regimens were dominated with the 
exception of ledipasvir/sofosbuvir 12 strategy which was only 
slightly more effective (approximately 3 additional QALY 
weeks) but with an ICER of $283,927. 
 
Discussion 
In none of the cost-utility models presented for the three 
case studies was any consideration given to the possibility of 
generating and assessing evaluable predictions. The claims 
presented were, in fact, immune to failure as they were 
expressed in lifetime cost-per-QALY terms. The choice of a 
modeled or simulated Markov or similar process to consider 
hypothetical intervention options, stages of disease and 
literature based estimates of costs and QALYS was justified by 
reference to these techniques as accepted standards in cost-
effectiveness analysis. There was no discussion of the 
relevance of these standards to the criteria a formulary 
committee in the US might apply to competing interventions 
and the choice between competing treatment strategies. 
Rather, the NICE reference case model was accepted as 
appropriate for constructing competing claims and driving 
formulary decisions. The possible need to conform to the 
standards of normal science in developing evaluable 
hypotheses, evaluation and possible replication was not 
considered. This is an unfortunate oversight given increasing 
concerns with the ability to replicate RCT based claims and 
the possibility of outcome switching in presenting phase 3 
RCT results 22 23 24. Indeed, it should not be forgotten that just 
as the construction of cost-per-QALY claims rest on the 
acceptance of models driving indirect comparisons to support 
assumptions for comparative treatment effects, the indirect 
treatment effect claims make implicit assumptions as to the 
replicability of the component individual RCT claims. The 
possibility of reviewing the robustness and replicability of the 
individual phase 3 RCT claims was not addressed. 
 
The absence of testable claims means, for example, that 
there is no attempt within the report to suggest how the 
competing claims for mepolizumab plus the standard of care 
versus standard of care alone might be assessed and reported 
back to a formulary committee as part of an ongoing disease 
area and therapeutic review. There was no consideration of 
the possibility, first put forward in the WellPoint formulary 
guidelines in 2005, that to support formulary assessment, 
manufacturers might submit a protocol alongside their 
submission to propose how the claims might be evaluated 
and the results reported as part of ongoing disease area and 
therapeutic class reviews  25 26 27. Standards that have been 
recently put forward in the University of Minnesota Social 
and Administrative Pharmacy Program proposed Guidelines 
for Formulary Evaluations.  28. The key points in the proposed 
guidelines are: (i) to present claims for competing 
pharmaceutical products that are evaluable; (ii) to submit a 
protocol to detail how the claims are to be evaluated; (iii) for 
the manufacturer to underwrite the evaluation; and (iv) to 
report claims back to a formulary committee as input to 
ongoing disease area and therapeutic class reviews and 
subsequent replication. 
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It is also not clear how a health system, who may not have a 
notional threshold willingness-to-pay or even consider 
applying one, would interpret these results. Attempts to 
negotiate with GSK for a potential discount for mepolizumab, 
for example, could presumably be challenged by (i) the 
degree of belief or otherwise in relevance of the modeled 
claims when these are patently constructed and immune to 
failure and (ii) the appropriateness of assumed willingness-to-
pay thresholds. The only basis for the recommendations for 
unit price discounts for both mepolizumab and insulin 
degludec are the two constructed simulations.  
 
Competing Simulations 
Just as imaginary worlds yield imaginary claims, competing 
imaginary worlds can yield competing imaginary claims. In 
the absence of claims being subject to experimentation or 
systematic observation, there is no way to judge their relative 
merits. It is entirely possible to envisage a situation where 
competing manufacturers commission competing simulations 
to support their respective products. The sheer complexity of 
the typical simulation, the assumptions made to justify both 
the structure of the model in choice of mathematical 
framework, the choice of stages of disease and transition 
probabilities between health states, together with the 
selection of unit costs and the trawling of the literature to 
cobble together utilities for the various disease states, all 
admit to the feasibility of reverse engineering to generate a 
required endpoint. This holds irrespective of appeals to ISPOR 
standards and the application of sensitivity analyses and the 
exploration of various scenarios.  
 
If competing products yield competing claims, with the claims 
expressed as lifetime cost-per-QALY increments (justified in 
turn by an appeal to the standard of the NICE reference case), 
then the only way to judge the merits of the claims is, 
presumably, to subject the competing simulations to expert 
appraisal. In the UK, this is achieved by engaging evidence 
review groups (ERGs), usually from academic institutions to 
report on their assessment of the merits of a submitted 
model and to suggest, if they judge it appropriate, 
modifications to the model or to develop an entirely new 
model. Their deliberations are in turn assessed by the NICE 
Advisory Panel who may accept, reject or suggest 
modifications. At no stage, of course, is there any question of 
evaluable claims, experimentation or even replication. 
Whether such an appraisal will ever occur in the US is a moot 
point given the lack of interest in QALYs by health care 
systems.   
 
Adherence and Persistence 
An odd feature of the lifetime imaginary reference case 
methodology is the treatment of adherence and persistence. 
Apart from ‘involuntary’ discontinuation through death or 
discontinuation rates based on RCT experience, the reference 
case standards mandated by NICE say nothing about how the 
modeled or simulated claims should capture non-compliance 
with therapy. This is a curious oversight in lifetime cost-per-
QALY models as the evidence would suggest that patients are 
typically non-compliant with chronic therapy in a relatively 
short period of time. In general terms, within approximately 3 
years of an index prescription, less than 30% of patients are 
likely to have persisted with therapy and a significant 
proportion of these are likely to be non-adherent (medical 
possession ratio < 0.8). If this is the case then it seems 
pointless to construct lifetime cost-per-QALY models which 
assume that patients remain adherent (and hence persistent) 
with medications over 10, 20 or even 30 years.  
 
 
Why Choose QALYs? 
A further odd feature of current standards for models or 
simulations  is the choice of QALYs as the primary endpoint, 
with summary cost-per-QALY claims. Aficionados of utility 
measurement have a choice between direct measures of 
health states such as the variants of the rating scale, standard 
gamble and time trade off as well as opposed to a number of 
multi-attribute health status classification systems with 
preference scores 29. The latter including the Quality of Well-
being Scale (QWB), the various incarnations of the Health 
Utilities Index (HUI), the various EuroQol measures (EQ-5D) 
and constructs drawn from the SF family of instruments (e.g., 
SF-6D). 
 
While it is understandable if the QALY (e.g., the EQ-5D) is 
mandated, as it is with the NICE reference case (and 
enshrined in legislation), the situation in the US is quite 
different. With the failure some years ago of attempts to 
advocate a QALY reference case standard in the US and the 
apparent lack of interest, as noted above, by the 
overwhelming majority of health systems in QALY outcomes, 
to express comparative claims in QALY terms seems 
unhelpful 30. Indeed the chance that a QALY quality metric 
will be mandated in the US is effectively zero. This was made 
abundantly clear in the Affordable Care and Patient 
Protection Act (2010) which mandates that the Patient 
Centered Outcomes Research Group (PCORI) exclude 
discounted cost-per-QALY or similar discounting measures 
and threshold values for priority setting in health care 31.  
 
Of course, expressing outcomes in cost-per-QALY terms, 
apart from the choice of QALY, adds a further level of 
immunity to claims. If claims expressed in cost-per-QALY 
terms are open to evaluation then, in the absence of any 
health system capturing QALYS as part of routine data 
collection means that rather than relying on data vendors to 
support claims evaluation there will have to investment in a 
specific prospective study.  Realistically, this is unlikely to 
occur.  
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Challenges 
For those advocating and constructing imaginary worlds to 
support value claims in formulary decisions, the risk is that 
the claims are open to challenge. In the absence of claims 
expressed in evaluable terms, offering the opportunity for 
hypothesis testing and replication, those advocating 
imaginary world are in no different a position from those 
advocating intelligent design. There is no basis for rejecting 
any claims that are made. Different models created by 
different intelligent designers can compete, but not on the 
basis of hypotheses being evaluated. Model assumptions, 
inputs and mechanisms can be challenged, but without any 
necessary resolution outside of existential appeals to the 
standards proposed by professional groups. 
 
Consider a recent systematic review of modeled claims 
published in the Journal of Medical Economics in the 12 
months from January 2015 to December 2015. The review 
identified 31 cost-effectiveness papers.  None met the 
standards of normal science in generating testable 
predictions. Fifteen present lifetime cost-per-QALY models. A 
total of 30 of the papers were funded by manufacturers with 
29 supporting untestable claims for the manufacturers’ 
product. Clearly, these could be challenged by constructing 
competing models, but no one appears to have thought it 
worthwhile. The papers are probably best seen as marketing 
exercises. 
 
Conclusions 
By definition, imaginary worlds yield imaginary claims. If the 
standards of normal science are applied as the basis for 
separating science from pseudoscience are accepted, then 
modeled or simulated claims for pharmaceutical products 
and devices that are immune to failure are clearly in the 
epistemological pseudoscience space.  
 
However, it is not the intention here to discourage the 
construction of imaginary worlds to support value claims for 
pharmaceutical products and devices. After all, there may be  
health care systems (and this is certainly true of single payer 
systems in the UK, Ireland and New Zealand) who mandate 
reference case submissions. There may also be health 
systems in the US willing to accept imaginary world based 
value claims as ‘useful’ inputs to formulary decisions. But 
there may also be health systems that fail to see the merits of 
constructed value claims.  
 
Meeting the standards of normal science, setting the stage 
for claim evaluation, it always a challenge. The challenge, 
however, is more in the mindset of the analyst and the 
willingness to put the pursuit of pseudoscience to one side. If 
we have the skills and resources to build complex imaginary 
worlds, claiming to track the key features of a chronic disease 
over 20 or 30 years, then surely it would not be too much of a 
challenge to create modeled or simulated evaluable claims 
that focus on the short-term.  Perhaps then cost-
effectiveness models and simulations might contribute to the 
national three-part CMS aim of better care and better health 
with smarter spending 32. 
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